AUTHORS
Ziyu Feng, Jia Chen, PhD2, Haiping Dai3, Xiaohui Hu, PhD4, Yang Xu, MD5, Shengli Xue6, Huiying Qiu, MD7, Xiaowen Tang, MD8, Han Yue, MD,PhD9, Suning Chen, MD, PhD10, Depei Wu Sr, MD11, Ying Wang, MD, PhD12
AFFILIATIONS
1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
2 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
3 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
4 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
5 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
6 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
7 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
8 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
9 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
10 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
11 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
12 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
ABSTRACT
Background
The standard of care for CBFβ::MYH11+ AML is 7+3 induction followed by high-dose cytarabine consolidation. However, this approach carries substantial early mortality from severe myelosuppression and cumulative anthracycline-induced cardiotoxicity. Our previous studies have showed venetoclax plus a hypomethylating agent (VEN+HMA) induction achieved near-universal remission with deep MRD responses and reduced toxicity in CBFβ::MYH11+ AML.
However, given that anthracycline dose is a key determinant of remission and overall survival in conventional regimens, whether anthracycline-free approaches compromise long-term efficacy remains unknown. We conducted a prospective phase 2 trial for patients with newly diagnosed(ND) patients evaluating 2 cycles of VEN+HMA induction followed by 4 cycles of VEN + intermediate-/high-dose cytarabine (ID/HD-Ara-C) consolidation.
Methods
This prospective, single-arm phase 2 clinical trial (NCT06429098) enrolled adults with ND CBFβ::MYH11+ AML. All patients received two 28-day cycles of induction therapy with VEN+HMA, with VEN dose adjustments applied when co-administered with CYP3A inhibitors. Unfit patients continued the regimen until disease progression, unacceptable toxicity, or completion of 24 cycles. For fit patients, consolidation consisted of 4 cycles of VEN (400mg once daily on days 1–7) combined with ID/HD-Ara-C (1.5–2g/m² q12h for 6 doses). Patients who failed to achieve remission after 2 induction cycles or who relapsed during treatment were withdrawn from the study. Treatment response was assessed after each cycle. Bone marrow MRD was monitored by MFC (negativity <0.1%) and RT-qPCR for CBFβ::MYH11/ABL1. Complete molecular remission (CMR) was defined as a CBFβ::MYH11/ABL1 ratio < 0.01%. The primary endpoint was composite complete remission (CCR = CR + CRi) after 2 induction cycles. Secondary endpoints included the MRD negativity rate, overall survival (OS), and relapse-free survival (RFS). Data cutoff: June 15, 2026.
Results
Between January 2024 and June 2025, 37 patients (21 males and 16 females) were enrolled. The median age was 49 years (range: 18–71 years), with 8 patients (21.6%) aged ≥ 60 years. At diagnosis, the median white blood cell count was 25.6 × 10?/L, and the median bone marrow blast percentage was 55.0%. Next-generation sequencing (NGS) revealed that the most frequent concomitant mutations involved NRAS (64.9%, 24/37), KIT (45.9%, 17/37), KRAS (21.6%, 8/37), and FLT3-TKD (21.6%, 8/37). Of these patients, 4 received DEC+VEN and 33 received AZA+VEN.
After the first induction cycle, 36 patients (97.3%) achieved CCR, and 1 patient (2.7%) achieved partial remission (PR). Among the 36 patients, 33 (91.7%) achieved MFC-MRD negativity. The median CBFβ::MYH11/ABL1 transcript ratio was 0.62% (range: 0–44.79%). After 2 induction cycles, the patient with PR also achieved CR, yielding a 100% CCR rate; additionally, four patients achieved CMR after the second cycle. Except for 1 patient who experienced early hematologic relapse, the remaining 36 patients proceeded to consolidation therapy. One unfit patient achieved CMR after 8 cycles of VEN+HMA and remains on maintenance therapy. The other 35 fit patients proceeded to consolidation with ID/HD-Ara-C + VEN. Of these, 28 completed all 4 planned cycles, whereas the remaining 7 patients discontinued consolidation early: 2 underwent allo-HSCT at their own preference, 1 died of sepsis, and 4 were withdrawn due to relapse. The median follow-up of the cohort was 17.3 months (range, 3.6–29.8 months). At the last follow-up, 10 patients had relapsed (including 5 during the follow-up period), 6 had undergone allo-HSCT, and 2 had died. Of the 20 patients who achieved CMR during consolidation, only one had a molecular relapse. The estimated 2-year OS rate was 94.5% (95% CI, 87.4%~100%) and the 2-year RFS rate was 55.3% (95% CI, 35.2%–86.7%). Patients with fusion gene levels below the median after two induction cycles demonstrated a trend toward superior RFS. No other clinical parameters, including mutation profiles, showed a significant association with RFS. No unexpected adverse events were observed during the study.
Conclusion
The VEN+HMA regimen demonstrated favorable efficacy and tolerability as induction therapy for newly diagnosed adult CBFβ::MYH11+ AML, and its combination with VEN+ID/HD-Ara-C in consolidation yielded encouraging survival outcomes, supporting the feasibility of anthracycline-free strategies in this population.
DISCLOSURES
Ying Wang, MD, PhD: No relevant conflicts of interest to declare.